Sidley advised EOC Pharma in entering into an exclusive license agreement with Aadi Bioscience (Aadi) for the development and commercialization of ABI-009 (FYARRO) in Greater China including mainland China, Hong Kong, Macau, and Taiwan.
EOC Pharma is a leading biopharmaceutical company in China, specializing in oncology. Aadi is a Los Angeles-based biopharmaceutical company focusing on precision therapies for genetically defined cancers. FYARRO (ABI-009, sirolimus albumin-bound nanoparticles) is an mTOR inhibitor complexed with human albumin.
Under the license agreement, EOC Pharma will obtain exclusive rights to develop and commercialize ABI-009 in Greater China. EOC Pharma will be responsible for development, regulatory submissions, and commercialization in the territory. Aadi Bioscience retains full worldwide rights outside of the partnered territory.
The Sidley team was led by partner Lei Li, with support from senior China advisor Ling Chen.
Sidley is a multidisciplinary one-stop service shop in the market for life sciences clients. We advise clients across different stages of their life cycles, ranging from formation, corporate governance, and compliance operations in the startup period, to collaboration, licensing, commercialization, and filing in the business development phase, to initial public offering, refinancing, and bond/note issues in the capital raising stage, to domestic and overseas mergers and acquisitions, asset restructuring, equity incentive plans, and privatization transactions when clients expand their businesses.